• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4597351)   Today's Articles (5551)   Subscriber (49349)
Number Citation Analysis
76
Raynaud FI, Hayes A, Asad YJ, Johnson L, Henley AT, Caldwell JJ, Collins I, Garrett MD. Abstract B190: Pharmacokinetics of the AKT inhibitor CCT128930 from dried blood spots sampled from caudal bleeding compared with conventional cardiac puncture. Mol Cancer Ther 2011. [DOI: 10.1158/1535-7163.targ-11-b190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
77
Welford AJ, Collins I. The 2,11-cyclized cembranoids: cladiellins, asbestinins, and briarellins (period 1998-2010). JOURNAL OF NATURAL PRODUCTS 2011;74:2318-2328. [PMID: 21970540 DOI: 10.1021/np200125v] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
78
Smyth LA, Matthews TP, Collins I. Design and evaluation of 3-aminopyrazolopyridinone kinase inhibitors inspired by the natural product indirubin. Bioorg Med Chem 2011;19:3569-78. [DOI: 10.1016/j.bmc.2011.03.069] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2011] [Revised: 03/28/2011] [Accepted: 03/31/2011] [Indexed: 01/09/2023]
79
Lainchbury M, Collins I. Checkpoint kinase inhibitors: a patent review (2009 - 2010). Expert Opin Ther Pat 2011;21:1191-210. [PMID: 21599421 DOI: 10.1517/13543776.2011.586632] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
80
Anderson VE, Walton MI, Eve PD, Boxall KJ, Antoni L, Caldwell JJ, Aherne W, Pearl LH, Oliver AW, Collins I, Garrett MD. CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 2011;71:463-72. [PMID: 21239475 DOI: 10.1158/0008-5472.can-10-1252] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
81
Gately K, Collins I, Forde L, Al-Alao B, Young V, Gerg M, Feuerhake F, O’Byrne K. A Role for IGF-1R–Targeted Therapies in Small-Cell Lung Cancer? Clin Lung Cancer 2011;12:38-42. [DOI: 10.3816/clc.2011.n.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
82
Yap TA, Walton MI, Hunter LJK, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther 2010;10:360-71. [PMID: 21191045 DOI: 10.1158/1535-7163.mct-10-0760] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
83
Whelligan DK, Solanki S, Taylor D, Thomson DW, Cheung KMJ, Boxall K, Mas-Droux C, Barillari C, Burns S, Grummitt CG, Collins I, van Montfort RLM, Aherne GW, Bayliss R, Hoelder S. Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization. J Med Chem 2010;53:7682-98. [PMID: 20936789 PMCID: PMC2972649 DOI: 10.1021/jm1008727] [Citation(s) in RCA: 57] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
84
Caldwell JJ, Welsh EJ, Matijssen C, Anderson VE, Antoni L, Boxall K, Urban F, Hayes A, Raynaud FI, Rigoreau LJM, Raynham T, Aherne GW, Pearl LH, Oliver AW, Garrett MD, Collins I. Structure-based design of potent and selective 2-(quinazolin-2-yl)phenol inhibitors of checkpoint kinase 2. J Med Chem 2010;54:580-90. [PMID: 21186793 DOI: 10.1021/jm101150b] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
85
van Montfort RLM, Collins I. Fragment-based methods in drug discovery: it's the small things that matter. Curr Top Med Chem 2010;9:1676-7. [PMID: 20044917 DOI: 10.2174/156802609790102428] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
86
Collins I, Doyle P, King F, O'Donnell D. Introduction of a simple Web-based calculator for drug dosing. IRISH MEDICAL JOURNAL 2010;103:251-252. [PMID: 21049590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
87
Hayward DG, Newbatt Y, Pickard L, Byrne E, Mao G, Burns S, Sahota NK, Workman P, Collins I, Aherne W, Fry AM. Identification by high-throughput screening of viridin analogs as biochemical and cell-based inhibitors of the cell cycle-regulated nek2 kinase. ACTA ACUST UNITED AC 2010;15:918-927. [PMID: 20664067 DOI: 10.1177/1087057110376537] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
88
Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. CHEMISTRY & BIOLOGY 2010;17:561-77. [PMID: 20609406 PMCID: PMC2905514 DOI: 10.1016/j.chembiol.2010.05.013] [Citation(s) in RCA: 206] [Impact Index Per Article: 14.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 04/07/2010] [Revised: 05/08/2010] [Accepted: 05/24/2010] [Indexed: 01/09/2023]
89
Haydon DJ, Bennett JM, Brown D, Collins I, Galbraith G, Lancett P, Macdonald R, Stokes NR, Chauhan PK, Sutariya JK, Nayal N, Srivastava A, Beanland J, Hall R, Henstock V, Noula C, Rockley C, Czaplewski L. Creating an antibacterial with in vivo efficacy: synthesis and characterization of potent inhibitors of the bacterial cell division protein FtsZ with improved pharmaceutical properties. J Med Chem 2010;53:3927-36. [PMID: 20426423 PMCID: PMC2874265 DOI: 10.1021/jm9016366] [Citation(s) in RCA: 86] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
90
Hilton S, Naud S, Caldwell JJ, Boxall K, Burns S, Anderson VE, Antoni L, Allen CE, Pearl LH, Oliver AW, Aherne GW, Garrett MD, Collins I. Corrigendum to “Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2” [Bioorg. Med. Chem. 18 (2010) 707]. Bioorg Med Chem 2010. [DOI: 10.1016/j.bmc.2010.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
91
Anderson VE, Eve PD, Walton MI, Caldwell JJ, Pearl LH, Oliver AW, Collins I, Garrett MD. Abstract 3503: CCT241533 is a novel, potent and selective inhibitor of CHK2 and potentiates the cellular effects of PARP inhibitors. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-3503] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
92
Walton MI, Eve PD, Hayes A, Valenti M, Brandon ADH, Box G, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD. Abstract 3518: Preclinical pharmacology of the novel, potent & selective CHK1 inhibitor SAR-020106. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-3518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
93
Yap TA, Walton MI, Hunter L, Grimshaw K, Valenti M, Eve P, Heaton SP, Pickard L, Caldwell JJ, Thompson N, de Bono JS, Kaye SB, Eccles SA, Workman P, Collins I, Garrett MD. Abstract 4481: First report of preclinical pharmacology of two novel potent AKT inhibitors and development of pharmacodynamic (PD) biomarkers in tumor and surrogate tissue. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-4481] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
94
Sharp SY, Jones K, Cheung KM, Prodromou C, Roe SM, Pearl LH, Collins I, McDonald E, Workman P. Abstract 2677: A detailed analysis of protein binding and biological activity of methoxy-substituted resorcinylic isoxazole amide HSP90 inhibitors. Cancer Res 2010. [DOI: 10.1158/1538-7445.am10-2677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
95
McHardy T, Caldwell JJ, Cheung KM, Hunter LJ, Taylor K, Rowlands M, Ruddle R, Henley A, de Haven Brandon A, Valenti M, Davies TG, Fazal L, Seavers L, Raynaud FI, Eccles SA, Aherne GW, Garrett MD, Collins I. Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). J Med Chem 2010;53:2239-49. [PMID: 20151677 PMCID: PMC2832868 DOI: 10.1021/jm901788j] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
96
Smyth LA, Matthews TP, Horton PN, Hursthouse MB, Collins I. Synthesis and reactivity of 3-amino-1H-pyrazolo[4,3-c]pyridin-4(5H)-ones: development of a novel kinase-focussed library. Tetrahedron 2010. [DOI: 10.1016/j.tet.2010.02.047] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
97
Walton MI, Eve PD, Hayes A, Valenti M, De Haven Brandon A, Box G, Boxall KJ, Aherne GW, Eccles SA, Raynaud FI, Williams DH, Reader JC, Collins I, Garrett MD. The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Mol Cancer Ther 2010;9:89-100. [PMID: 20053762 DOI: 10.1158/1535-7163.mct-09-0938] [Citation(s) in RCA: 69] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
98
Davies BR, Dudley P, Cosulich S, Luke R, Thompson N, Collins I, McHardy T, Garrett M, Ogilvie D. Abstract C208: CCT129254 (AT11854) is a well tolerated, orally bioavailable inhibitor of AKT/PKB with pharmacodynamic and antitumor activity in a range of xenograft models. Mol Cancer Ther 2009. [DOI: 10.1158/1535-7163.targ-09-c208] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
99
Hilton S, Naud S, Caldwell JJ, Boxall K, Burns S, Anderson VE, Antoni L, Allen CE, Pearl LH, Oliver AW, Wynne Aherne G, Garrett MD, Collins I. Identification and characterisation of 2-aminopyridine inhibitors of checkpoint kinase 2. Bioorg Med Chem 2009;18:707-18. [PMID: 20022510 DOI: 10.1016/j.bmc.2009.11.058] [Citation(s) in RCA: 43] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2009] [Revised: 11/16/2009] [Accepted: 11/27/2009] [Indexed: 11/28/2022]
100
Davies T, Woodhead S, Collins I. Fragment-Based Discovery of Inhibitors of Protein Kinase B. Curr Top Med Chem 2009;9:1705-17. [DOI: 10.2174/156802609790102419] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2009] [Accepted: 10/10/2009] [Indexed: 11/22/2022]
PrevPage 4 of 8 1234578Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA